ATE457721T1 - An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen - Google Patents

An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen

Info

Publication number
ATE457721T1
ATE457721T1 AT06724260T AT06724260T ATE457721T1 AT E457721 T1 ATE457721 T1 AT E457721T1 AT 06724260 T AT06724260 T AT 06724260T AT 06724260 T AT06724260 T AT 06724260T AT E457721 T1 ATE457721 T1 AT E457721T1
Authority
AT
Austria
Prior art keywords
dnanoparticles
titanium dioxide
active ingredients
formulations containing
pharmaceutical formulations
Prior art date
Application number
AT06724260T
Other languages
English (en)
Inventor
Alberto Marra
Alessandro Dondoni
Carlo Bignozzi
Renato Canevotti
Gian Paolo Negrisoli
Valeria Dissette
Original Assignee
Flamma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamma Spa filed Critical Flamma Spa
Application granted granted Critical
Publication of ATE457721T1 publication Critical patent/ATE457721T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT06724260T 2005-05-26 2006-04-12 An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen ATE457721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68453205P 2005-05-26 2005-05-26
PCT/EP2006/003348 WO2006125496A2 (en) 2005-05-26 2006-04-12 Pharmaceutical formulations comprising active pharmaceutical principles absorbed on titanium dioxide nanoparticles

Publications (1)

Publication Number Publication Date
ATE457721T1 true ATE457721T1 (de) 2010-03-15

Family

ID=37452388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06724260T ATE457721T1 (de) 2005-05-26 2006-04-12 An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen

Country Status (5)

Country Link
US (1) US20080206347A1 (de)
EP (1) EP1888046B1 (de)
AT (1) ATE457721T1 (de)
DE (1) DE602006012310D1 (de)
WO (1) WO2006125496A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103557A2 (en) 2006-03-09 2007-09-13 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
WO2008135093A1 (en) * 2007-05-08 2008-11-13 Nm Tech Nanomaterials Microdevice Technology Ltd. Products comprising an anti-microbial composition based on titanium dioxide nanoparticles
FR2943539B1 (fr) * 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
WO2015095317A1 (en) 2013-12-19 2015-06-25 3M Innovative Properties Company Articles comprising self-assembled layers comprising nanoparticles with a phosphorous surface treatment
CN110090305A (zh) * 2019-03-15 2019-08-06 温州医科大学附属口腔医院 一种负载唑来膦酸的介孔二氧化钛

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2331097A1 (de) * 1973-06-19 1975-01-16 Battelle Institut E V Depotsystem fuer pharmazeutische oder kosmetische praeparate mit retardwirkung fuer aeusserliche anwendung
FR2451194A1 (fr) * 1979-03-16 1980-10-10 Merieux Inst Nouveau medicament a base de ganglioside notamment pour le traitement du cholera, et compositions pharmaceutiques le contenant
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6086928A (en) * 1998-02-05 2000-07-11 Newly Weds Foods, Inc. Whitened food products and process for producing the same
JP2005511761A (ja) * 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
WO2003032959A1 (en) * 2001-10-15 2003-04-24 Bosch William H Nanoparticulate compositions comprising inorganic cores
ATE540671T1 (de) * 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien

Also Published As

Publication number Publication date
EP1888046A2 (de) 2008-02-20
WO2006125496A2 (en) 2006-11-30
EP1888046B1 (de) 2010-02-17
DE602006012310D1 (de) 2010-04-01
US20080206347A1 (en) 2008-08-28
WO2006125496A3 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
EP2444072A3 (de) Nichtmukoadhäsive Filmdosierungsformen
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AP2012006231A0 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
DK1957110T3 (da) Fremgangsmåde til fremstilling af tygbare doseringsformer til lægemiddeladministration og produkter dermed
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
IL191804A0 (en) Solid dispersion containing an active ingredient and tablets for oral administration containing the same
TW200616640A (en) Novel pharmaceutical formulations of active principles
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
WO2010127205A3 (en) Fixed dose drug combination formulations
ATE498396T1 (de) Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes
HK1208222A1 (en) Modified release formulations for oprozomib
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
MY146988A (en) Fexofenadine suspension formulation
WO2006108692A3 (en) Dosage form for oral administration of a vitamin
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
ATE457721T1 (de) An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
ECSP109871A (es) Soluciones farmacéuticas orales que contienen telbivudina
WO2004096125A3 (en) Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties